Personalized functional profiling using ex-vivo patient-derived spheroids points out the potential of an antiangiogenic treatment in a patient with a metastatic lung atypical carcinoid. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Kim, Hichul; El-Khoury, Victoria; Schulte, Nadine; Zhan, Tianzuo; Betge, Johannes; Cousin, Loic; Felli, Emanuele; Pessaux, Patrick; Ogier, Arnaud; Opitz, Oliver G; Ku, Bosung; Ebert, Matthias P; Kwon, Yong-Jun
• Is Part Of: Cancer biology & therapy. Volume 23:Issue 1(2022)
• Page Start: 96
• Page End: 102
• Publication Date: 2022-12-31
• Subjects: Personalized functional profiling -- drug screening -- pharmacotyping -- personalized medicine -- precision medicine -- spheroids -- neuroendocrine tumors -- lung carcinoid -- antiangiogenic therapy; 616.99406
• DOI: 10.1080/15384047.2021.2021042
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in ex-vivo spheroids obtained from the patient's liver metastasis to identify potential therapeutic options. The drug screening results revealed cediranib, an antiangiogenic drug, as a hit drug for this patient, from a library of 66 Food and Drug Administration (FDA)-approved and investigational drugs. Based on the PFP results and the reported evidence of clinical efficacy of bevacizumab and capecitabine combination in gastro-intestinal neuroendocrine tumors, this combination was given to the patient. Four months later, the pleural effusion and pleura carcinosis regressed and the liver metastasis did not progress. The patient experienced 2 years of a stable disease under the PFP-guided personalized treatment.